Auris Medical : Corporate Presentation May 2021

Innovative Treatments in Neurotology, Rhinology and Allergy and CNS Disorders

Corporate Presentation

May 2021

NASDAQ: EARS | Contact: [e-mail]

Forward-looking Statements

This presentation may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Auris Medical's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those

contemplated by these statements. These risks and uncertainties include, but are not limited to, the approval and timing of commercialization of AM- 301, Auris Medical's need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Auris Medical's product candidates, the clinical utility of Auris Medical's product candidates, the timing or likelihood of regulatory filings and approvals, Auris Medical's intellectual property position and Auris Medical's financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medical's capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Auris Medical's Annual Report on Form 20-F for the year ended December 31, 2020, and in Auris Medical's other

filings with the SEC, which are available free of charge on the Securities Exchange Commission's website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Auris Medical or to persons acting on behalf of Auris Medical are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Auris Medical does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.

1	www.aurismedical.com | NASDAQ: EARS

Dedicated to Targeted Drug Delivery

Innovative Treatments in Neurotology, Rhinology and Allergy and CNS Disorders

The Company

Key Development Programs

• Founded in 2003
• Pioneer role in neurotology
• Expanding into rhinology and allergy and CNS disorders
• Focus on nasal spray products
• Headquartered in Hamilton, Bermuda
• Operations in Basel, Switzerland
• IPO in August 2014 on Nasdaq (EARS)

Betahistine nasal spray for treating acute vertigo

• Reformulation of oral betahistine (histamine analog)
• Intranasal delivery provides 5-29 x higher plasma exposure
• Global market potential > $1bn in vertigo

Drug-free nasal spray to protect against airborne viruses and allergens

• Applies thin gel film on nasal mucosa
• Triple action: mechanical barrier, binds particles, humidifies mucosa
• US market for OTC allergy remedies > $4bn

2	www.aurismedical.com | NASDAQ: EARS

Investment Highlights

Large U.S. and	Great unmet	Relatively low	Existing	Several data	Partnering	Seeking to
global market	medical need	development risk	markets	events coming	potential	increase
opportunities				up in 2021		shareholder
						value

3	www.aurismedical.com | NASDAQ: EARS

Project Pipeline

Partnering ProjectsActive Projects

Product	Indication	Preclin.	Phase 1	Phase 2	Phase 3	Next Key Milestones*
AM-125	Vertigo					Phase 2 enrollment completed
Betahistine nasal spray					(Q3 2021)
AM-201	Antipsychotic-					IND
Betahistine nasal spray	induced weight gain					(Q4 2021)
BentrioTM (AM-301)**	Airborne viruses and					Market launch in selected EU countries
Drug-free nasal spray	allergens					(Q2 2021)
Sonsuvi® (AM-111)	ASNHL (sudden					Preparing for Phase 3 study Partnering
Brimapitide	deafness)					/ non-dilutive funding
Keyzilen® (AM-101)	Acute inner ear					Preparing for Phase 2/3 study
Esketamine	tinnitus					Partnering / non-dilutive funding
AM-102	Tinnitus					Select lead compound
Undisclosed

• Dates of key milestones are indicative and subject to change
• Medical device; drug development phases do not apply

4	www.aurismedical.com | NASDAQ: EARS